Vijay Barathan
Life Science Partner @ GM&C Life Sciences Fund
London, United Kingdom
Vijay Barathan is a seed investor at GM&C Life Sciences Fund in London focused on Health Care and Medical. Before Optum Ventures, Vijay was a life science partner with Catapult’s GM&C Life Sciences Fund leading and managing investments across life sciences with a specialist focus on digital health. Vijay has invested in data driven companies targeting respiratory health, complications of diabetes, patient safety, consent and education.Prior tothis, he was chief investment officer at a health care IP commercialisation company focused on digital health, diagnostics and therapeutics investments. He was previously a health care investment banker at Peel Hunt and Piper Jaffray, looking after listed health care clients as well as undertaking IPO, M&A, private placement and secondary fundraising transactions.Vijay began his career in medicine and worked as a doctor for the NHS. He qualified from Guy’s Kings and St. Thomas Medical School in London and holds a MBBS in Medicine and a B.S. in Development Neurobiology.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 64%
Last updated:
For AI agents: llms.txt
Industries Vijay Barathan invests in
Stages Vijay Barathan invests in
Countries Vijay Barathan invests in
Investment Focus
Industry
- Health Care 8 (73%)
- Medical 4 (36%)
- Software 2 (18%)
- Analytics 2 (18%)
- Pharmaceutical 2 (18%)
Stage
- Seed 3 (27%)
- Series A 3 (27%)
- Series B 1 (9%)
- Series C 1 (9%)
- Funding Round 1 (9%)
Country
- United Kingdom 6 (55%)
- Ireland 1 (9%)
- Singapore 1 (9%)
- United States 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Holmusk
|
Holmusk is developing a Real-World Evidence platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions. It works by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that can be used to maketreatment decisions, as well as the commercialization of new drugs.Holmusk was founded in 2015 and is based in Singapore, Malaysia, and the USA. | Venture - Series Unknown / Dec 06, 2021 | |
Caresyntax
|
Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $130M / Series C / Sep 16, 2021 | |
Ultromics
|
Ultromics develops AI-powered software solutions to assist in cardiovascular disease diagnosis through echocardiography. The company provides platforms that support clinicians in interpreting echocardiogram data by applying machine learning to detect patterns and abnormalities that may indicate heart conditions. Ultromics offers its flagshipproduct, EchoGo, which automates the analysis of echocardiograms and delivers quantitative reports on cardiac function and structure. The software integrates with existing clinical workflows and is designed to enhance decision-making consistency while reducing variability in scan interpretation. Ultromics focuses on leveraging data-driven approaches to support early detection of conditions such as heart failure and coronary artery disease. Its technology is built on research collaborations and large-scale clinical datasets, aiming to improve diagnostic outcomes and support clinical efficiency. | $32.8M / Series B / Aug 16, 2021 | |
|
Caresyntax
|
Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $100M / Series C / Apr 28, 2021 | |
|
Holmusk
|
Holmusk is developing a Real-World Evidence platform in behavioral health and chronic diseases to expand data-driven, evidence-based care for people managing behavioral health conditions. It works by bringing together specialty behavioral health data and Holmusk’s novel analytics platform to deliver evidence-based insight that can be used to maketreatment decisions, as well as the commercialization of new drugs.Holmusk was founded in 2015 and is based in Singapore, Malaysia, and the USA. | $21.5M / Series A / May 18, 2020 | |
Rinicare
|
Rinicare is Lancaster-based SME that offers innovative technology solutions for healthcare applications. | Aug 16, 2018 | |
Acea Health
|
Acea Health is a digital healthcare company developing an application called Flynotes - a new digital consent platform. Flynotes analyses a number of factors, including the patient’s background, to deliver personalised risks and benefits. Flynotes aims to be the go-to solution for consent in healthcare. . | Seed / Jan 24, 2018 | |
SurgaColl
|
SurgaColl Technologies is a medical device company developing novel tissue regeneration products for the surgical treatment of diseases of the bone, cartilage and other human tissue. Based on technology developed at the Tissue Engineering Research Group (TERG) of the Royal College of Surgeons in Ireland (RCSI), headed by Professor Fergal O’Brien,the company aims to become a leader in the field of regenerative medical devices. | $4.1M / Series A / Jan 01, 2018 | |
Nexus Labs (Surgical Teaching)
|
Nexus Labs is an interactive learning resource for medical students. | Seed | |
Maxwellia
|
Maxwellia is a pioneering ‘prescription to over the counter’ medicines company which specialises in ‘switching’ - the conversion of prescription medicines into branded versions that can be bought without a prescription, over the counter (OTC). | $917K / Seed | |
| See all 11 investments → | |||
Co-Investors
Intel Capital
3 deals together
Health Catalyst Capital
2 deals together
OCTAVE Capital
2 deals together
Relyens
2 deals together
surgical.ai
2 deals together
Vesalius Biocapital Partners
2 deals together
About GM&C Life Sciences Fund
The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
GM&C Life Sciences Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Whitcombe
Venture Partner
|
|||
David Whitcombe
Venture Partner
|
|||
Chris Spencer
Venture Partner
|
|||
Gareth King
Life Science Partner
|
|||
Kevin D'Silva
Venture Partner - Medical Devices
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Vijay Barathan invest in?
Vijay Barathan invests primarily in Health Care, Medical and Software startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Vijay Barathan last invest?
The most recent investment recorded for Vijay Barathan closed in Dec 2021. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
